Patients must have histopathologically /cytologically confirmed advanced solid tumor which is refractory to standard therapeutic options, or for which there are no standard therapeutic options, or for whom paclitaxel is an appropriate palliative treatment option (patients for whom paclitaxel or nab-paclitaxel are established treatment options with a proven survival benefit in first line will be excluded)
Histologically confirmed advanced solid tumors with no clear curative treatment options available after at least 1 prior systemic anticancer therapy.
Has failed (refractory) or relapsed after no more than 2 prior regimens, and for whom for whom no other standard therapy options are available.
no standard therapeutic options available (to be supplemented)
Previously treated for advanced cancer with no additional therapy options available known to prolong survival.
The patient has given written informed consent after the nature of the study and alternative treatment options have been explained
Dose escalation:\r\n* Any locally advanced or metastatic solid tumor malignancy with no curative treatment options available
Progression on standard therapy, not a candidate for further chemotherapy or patient declines other options
Must have failed or be unable to tolerate or refused other available Food and Drug Administration (FDA) approved effective therapies; NOTE: patients should not have other treatment options considered curative
Have been informed of other treatment options
Patients for whom other curative or established standard-of-care therapeutic options with acceptable morbidity exist
Patients with options for treatment that are known to be curative are not eligible.
Patients must have disease that has relapsed after or is refractory to at least 2 lines of standard therapy; the remaining standard treatment options are unlikely to be effective in the opinion of the treating physician, or patient is felt to be ineligible for such therapies or the patient refuses such therapies; patients who have undergone autologous stem cell transplant are eligible as long as they meet all other criteria
Have been informed of other treatment options
Formal evaluation by the Liver Tumor Program at University of Taxes Southwestern (UTSW) and/or review at the Liver Tumor Board: all patients should be fairly and prudently informed of their treatment options; to this end, all patients must be evaluated before brachytherapy treatment for discussion and consideration of other options for treatment of liver cancer including surgical resection
Have been informed of other treatment options and is not a candidate for standard treatment options or stem cell transplant at the time of enrollment
Patients with options for treatment that are known to be curative are not eligible
Patients who do not have other options of treatment, based on consensus recommendation of the multidisciplinary SSRS tumor board; patients will have an appropriate medical oncologist for their disease
No available curative treatment options, a limited prognosis of several months to < 2 years anticipated survival with currently available therapies, and progressive or relapsed disease
Have been informed of other treatment options
Male or female subjects with AML with no available curative treatment options using currently available therapies
CAPMATINIB INCLUSION CRITERIA: Prior treatment with at least one Food and Drug Administration (FDA)-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
CERITINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
REGORAFENIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
ENTRECTINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
No known effective therapy options are available
Patients with curative treatment options
Previously treated for advanced cancer and there are no curative therapy options available
Previously treated for advanced cancer with no additional therapy options available known to prolong survival
Progression by RANO criteria following all standard treatment options with known survival benefit
Patients must have received at least one course of chemotherapy consisting of a platinum doublet and must have no acceptable standard treatment options
Patients must have failed standard therapy and at the time of study entry have recurrent, progressive or refractory disease with no known curative options
Subjects must have primary or metastatic liver malignancies for which are surgically unresectable, and exhausted all standard therapeutic options to be eligible for this study
Patients with rapidly advancing systemic disease, especially those without good options of systemic treatment for their disease outside the CNS (Cohort D)
no standard therapy options
3. Morphologically documented relapsed/refractory AML as defined by World Health Organization (WHO) criteria after at least 1 prior therapy for AML with the exception of hydroxyurea, and not felt to have curative treatment options per treating physician, or the patients themselves are unwilling to consider curative treatment options.
Have been informed of other treatment options
Histologically or cytologically proven diagnosis of hematologic malignancies for whom all standard therapy options have failed
A disease expert at the study site must have a detailed discussion with the patient of other treatment options which either have been approved by the FDA or are part of or relevant to the standard care of patients with B-CLL/SLL in the multiply relapsed setting
Histologic proof of cancer which is now not amenable to alternative curative or clearly superior standard treatment options
Has relapsed or refractory disease and no standard treatment options as determined by locally or regionally available standards of care and treating physician's discretion
Patient is fit to receive the randomization options for which he is being considered
Recurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator.
Histologic proof of cancer which is now not amenable to curative standard treatment options
Have been informed of other treatment options
Patients who declined standard therapies or whose physicians determined they were not suitable for standard therapy options are eligible
Advanced or metastatic colorectal cancer with no curative options available and progression on previous standard therapy, including an EGFR inhibitor if KRAS wild-type
Have been informed of other treatment options.
Must have advanced disease and no standard treatment options as determined by locally/regionally available standards of care and treating physician's discretion
Patient with extensive systemic disease and without reasonable systemic treatment options.
Participants must have adenocarcinoma of the prostate that is metastatic or unresectable and for which standard curative options do not exist
Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.
Subject has no available or declines curative treatment options such as allogeneic stem cell transplant (SCT) and has limited prognosis (< 2 years survival) with currently available therapies
Have been informed of other treatment options
Phase Ia: Patients may have de novo metastatic disease, or documented progression despite any number of prior therapies; patients must have no curative or other effective therapeutic options available
(Arm A) relapsed or refractory CLL/SLL and require treatment in the opinion of the Investigator. Subject must have relapsed following or be refractory to standard treatments such as fludarabine based regimens (F, FC, FR, FCR) or alkylator (chlorambucil, bendamustine) based regimens. In addition, there are no other curative options, and the subject has exhausted options that would be considered standard of care, or
(Arm B) relapsed or refractory NHL and require treatment in the opinion of the Investigator. Subject must have histologically documented diagnosis of NHL as defined in the World Health Organization classification scheme, except as noted in the exclusion criteria. Subject must have relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens. In addition, there are no other curative options, and the subject has exhausted options that would be considered standard of care. Subjects with other lymphoproliferative diseases can be considered in consultation with the Abbott medical monitor.
Patient must not have curative options available (e.g. a single metastatic focus in the liver in a patient with MCRC eligible for metastasectomy).
Randomized cohort: resistant or intolerant to prior ruxolitinib therapy. Documentation by the Investigator that the patient has exhausted available treatment options (eg, resistant or intolerant to hydroxyurea, etc).
Subjects with pathologically documented AML that has failed standard treatment, or subjects without prior therapy who refuse standard treatment options
Have been informed of other treatment options.
Therapeutic Options: Patients must be ineligible or inappropriate for other treatment regimens known to have curative potential.
Relapsed or refractory disease (as defined below) for which patients are ineligible for or have exhausted standard therapeutic options that would be considered standard of care
Pre-existing limitations on care options, (Do Not Attempt Resuscitation Orders, etc).
Disease that has progressed despite other available standard treatment options, based on what is clinically indicated according to the investigator's clinical and medical judgment, including:
Have been informed of other treatment options
Other therapeutic and palliative options have been exhausted
Declined all standard treatment options
Have not had their initial doctor consultation to discuss treatment options
Ineligible for or have exhausted standard therapeutic options
Male or female patients, ages 12 years and older, with relapsed or refractory B-ALL who have failed, or are intolerant to, any established therapy; or for whom no other treatment options are available.
